Evidence map›Paper›PMID 38066376›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Genetic Engineering of Therapeutic Phages Using Type III CRISPR-Cas Systems.

Courtney M Hill, Asma Hatoum-Aslan

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Courtney M HillDepartment of Microbiology, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Asma Hatoum-AslanDepartment of Microbiology, University of Illinois at Urbana-Champaign, Urbana, IL, USA. ahatoum@illinois.edu.

Funding

Engineering picoviruses with defined host range to combat drug-resistant staphylococciR21AI156636 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DOKLAND, TERJE, HATOUM, ASMA · 2021 to 2022
$434k
NIAID NIH HHS R21 AI156636
6 · The paper itself

Abstract

The functional characterization of "hypothetical" phage genes is a major bottleneck in basic and applied phage research. To compound this issue, the most suitable phages for therapeutic applications-the strictly lytic variety-are largely recalcitrant to classical genetic techniques due to low recombination rates and lack of selectable markers. Here we describe methods for fast and effective phage engineering that rely upon a Type III-A CRISPR-Cas system. In these methods, the CRISPR-Cas system is used as a powerful counterselection tool to isolate rare phage recombinants.

Indexed as

BacteriophagesCRISPR-Cas SystemsGenetic EngineeringBacteriophage engineeringCRISPR-Cas10Phage genome editingStaphylococciType III-A CRISPR-Cas

Identifiers

PMID38066376
PMCPMC13496385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.